
Compugen Investor Relations Material
Latest events

Q3 2024
Compugen
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Compugen Ltd
Access all reports
Compugen Ltd. is a clinical-stage therapeutic discovery and development company that focuses on immuno-oncology and autoimmune diseases. The company leverages a predictive computational discovery platform to identify novel drug targets and develop therapeutic products. Its pipeline includes a range of products in clinical trials, such as COM701 and COM902, which target various cancers including non-small cell lung cancer and head and neck squamous cell carcinoma. The company is headquartered in Holon, Israel, and its shares are listed on the NASDAQ.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
CGEN
Country
🇺🇸 United States